[Ip-health] Letter: Over 30 civil society organisations urge EU to abolish supplementary protection certificates mechanism

Dimitri Eynikel Dimitri.Eynikel at msf.org
Mon Sep 11 04:41:01 PDT 2017

Please feel free to use and share widely. All documents can also be found https://www.msfaccess.org/content/letter-over-30-civil-society-organisations-urge-eu-abolish-supplementary-protection

We will also tweet about the submission this afternoon.


Letter: Over 30 civil society organisations urge EU to abolish supplementary protection certificates mechanism

In an open letter and open submission, thirty-three civil society organisations have called on the European Commission to abolish the supplementary protection certificates (SPC) mechanism and to stop encouraging the inclusion of SPCs - or similar mechanisms, such as patent term extensions - in free trade agreements with other countries.

Supplementary protection certificates (SPCs) expand and extend existing monopoly rights of pharmaceutical corporations. As such, SPCs lead to higher medicines prices by preventing generic competition for a longer period of time and prolonging the monopolies of originator pharmaceutical companies.

SPCs were initially introduced, and partly justified, based upon pharmaceutical companies' concern that they were no longer given a fair opportunity to recover their investments in research and development (R&D). However, SPCs are counterproductive to stimulating innovation. They create incentives for companies to focus on prolonging monopolies through controversial 'evergreening' strategies, including the filing of multiple patents and pursuit of prolonged patent terms for the same medicine. SPCs do not create incentives for innovation targeting unmet public health needs; rather, they disproportionately empower commercial interests and encourage pharmaceutical companies to prioritise R&D only in profitable markets.

High prices of lifesaving medicines have become a global challenge, in Europe as well as in the developing world. Prolonged market exclusivity through SPCs has enabled companies to charge unaffordable prices, as demonstrated - in detail and with concrete examples - in the full submission text.

Co-signing organisations
1.            Médicins sans Frontières (MSF) Access Campaign
2.            Wemos
3.            STOPAIDS UK
4.            Global Health Advocates France (GHA)
5.            Just Treatment
6.            Health Action International (HAI)
7.            PRAKSIS
8.            Global Justice Now
9.            Médecins du Monde
10.          Commons Network
11.          EKPIZO
12.          UAEM Europe
13.          Salud por Derecho
14.          All-Ukrainian Network of PLWHA
15.          "AGEP'C" Kazakhstan
16.          Prescrire
17.          Aktionsbündnis gegen Aids - Action against Aids Germany
18.          AIDES
19.          Public Eye
20.          Health Projects for Latvia
21.          Altroconsumo
22.          Access to Medicines Ireland (AMI)
23.          BUKO Pharma-Kampagne
24.          AIDS Action Europe
25.          IPPNW Germany (International Physicians for the Prevention of Nuclear War - Physicians for Social Responsibility)
26.          AIDES
27.          The International Society of Drug Bulletins (ISDB)
28.          Grupo de Ativistas em Tratamentos (GAT)
29.          Hepatitis Scotland
30.          Aids Hilfe (Austria)
31.          Oxfam
32.          European AIDS Treatment Group (EATG)
33.          MEZIS e.V. Germany

Dimitri Eynikel | EU policy and advocacy advisor A.I.
Access campaign  | Médecins Sans Frontières | Doctors Without Borders
T : +32 2 474 75 24| M: +32 476 86 32 54 | E : dimitri.eynikel at msf.org<mailto:dimitri.eynikel at msf.org> | www.msfaccess.org<http://www.msfaccess.org/>

More information about the Ip-health mailing list